Copied Pete's post from the swamp.Too good to leav
Post# of 72436
![Avatar](/images/ProfileImages/1207987678_3042_Picture 5.jpg)
Kelt
petemantx Tuesday, 11/27/18 12:51:39 PM
Re: nerby post# 249976 0
Post #
249980
of 249981
As you pointed out, Brilacidin has been shown to work against Ulcerative Colitis (UC).
UC, along with Crohn's Disease, make up Inflammatory Bowel Disease (IBD). IBD produces inflammation and bleeding ulcers within the lining of the large intestine (colon). It occurs when the immune system overreacts to bacteria and other substances in the digestive tract. It generally starts at the rectum and spreads to the colon.
The above definitions were taken from www.healthline.com/health/colitis#types-and-causes.
Some seem to mistakenly think Brilacidin in each separate indication is a new drug, while in reality it is the same drug but needing various delivery systems for varying indications. For Oral Mucositis (OM), sachets seem to be the most effective delivery system. For Proctosigmoiditis, which affects the rectum and lower portion of the colon, a foam/gel seems to be thought of as the most effective. For the upper and middle colon, which also includes the area where Crohn's Disease is found, a pill has been mentioned as the preferred delivery tool. This pill would most likely be governed by the pH level in the colon as to where it would dissolve so the drug can be pinpointed at the preferred location and thus be most effective.
As of today, we have the sachets developed but still need to finalize the foam/gel and pill delivery systems. Are these delivery systems attainable? IMO, based on talking to far more learned folks, they should prove no problem, especially to a BP. Will we have to test to make sure these new systems work? Yes, but that is a far cry than starting from scratch which some make it sound would be needed.
Each new indication and delivery system success will spur faster and faster development of Brilacidin for new applications so that one day it may rival the breadth of Humira as to its revenue streams. This is extremely important due to its inherent antibiotic and anti inflammatory properties.
IPIX didn't go to the jungles of New Guinea and have some witch doctor perform the IBD trials and take the pictures showing the improvement of the colon per the data board presentation at the recent NYC IBD Innovate 2018 show. I have heard that it was quite well received and those at the show weren't random bumpkins but the elite of IBD researchers in the world.
There is no doubt in my mind BP knows fully well the strength of Brilacidin as a powerful IBD treatment, they have no concerns in being able to develop the delivery systems for it, and they know that the OM/IBD indications are but a minor portion of the overall possibilities that Brilacidin possesses in becoming a huge commercial success.
To equate its value alone, much less in addition to Prurisol and Kevetrin, at the levels some are suggesting is ludicrous. Dreamers are laughed at by many as being unrealistic, but IPIX is for visionaries since it has already developed the products that will take it to heights that seem to be beyond the ability for many to wrap their heads around.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)